Fabry disease in donor kidneys with 3-and 12-year follow-up after transplantation

NDT Plus

Volumn 3, Issue 3, 2010, Pages 303-305

  Aasebø, Willy ^a,c   Strøm, Erik H ^a   Hovig, Torstein ^a   Undset, Liv H ^a   Heiberg, Arvid ^a   Jenssen, Trond ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

enzyme replacement therapy; Fabry disease; histological changes; kidney; transplantation

Indexed keywords

ALPHA GALACTOSIDASE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; ARTICLE; CASE REPORT; ENDOTHELIUM CELL; FABRY DISEASE; FOLLOW UP; GRAFT REJECTION; HISTOLOGY; HLA SYSTEM; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MALE; PODOCYTE; PRIORITY JOURNAL; WEGENER GRANULOMATOSIS;

EID: 77955943639     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfq036     Document Type: Article

References (6)

1. Sessa A, Meroni M, Battini G et al. Renal pathological changes in Fabry disease. J Inherit Metab Dis 2001; 24: 66-70
2. Gubler M-C, Lenoir G, Grünfeld J-P, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with Fabrys disease. Kidney Int 1978; 13: 223-235
3. Thurberg BL, Rennke H, Colvin RB et al. Globotriaosylceramide, accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62: 1933-1946
4. Germain DP, Waldek S, Banikazemi M et al. Sustained, long-term renal stabilization after 54 months of agalsidase ? therapy in patients with Fabry disease 2007; 18: 1547-1557
5. Marshall CB, Shankland S. Cell cycle regulatory proteins in podocyte health and disease. Nephron Exp Nephrol 2007; 106: e51-e59
6. Basic-Jukic N, Coric M, Kes P, Bubic-Filipi LJ, Pasinin J, Kokos I. Anderson-Fabry disease in kidneys from diseased donor. Am Transplant 2007; 7: 2829-2833